TP53INP1 and breast carcinoma: TP53INP1 suppresses gemcitabine resistance in pancreatic cancer, sorafenib resistance and DDP resistance in liver cancer, paclitaxel resistance in breast cancer, DDP resistance in lung cancer, etc. [39–42].